Independent Conference Highlights of the 2025 European Lung Cancer Congress *

Review slidesets, a ClinicalThought commentary, and expert analysis of key data from the 2025 ELCC.

Share

Program Content

1 Capsule Summaries

Activities

SAVANNAH
SAVANNAH: Phase II Trial of Savolitinib + Osimertinib for Advanced EGFRm NSCLC With MET Amplification or Overexpression After Progressing on Osimertinib
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 02, 2025

Expires: October 01, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.